Clinical trial
A Single-center, Open-label Study to Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors
NCT05579275 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-center, Open-label Study to Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- February 6, 2023
- Completion date
- April 28, 2027
- Enrollment
- 24 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
malignant solid tumors